P
RINCETON, NJ--AxCell Biosciences, a wholly owned subsidiary of Cytogen, has entered into a partnership with Compaq to develop a database software package that the companies said will help select promising drug targets from protein pathway data generated by AxCell. The program will be facilitated by Compaq’s Alpha, high-performance, 64-bit systems to deliver speed and scalability advantages.
Using high-throughput methods, with InforMax, AxCell said it is creating what it calls an Inter-Functional Proteomic Database to identify protein interactions and novel drug targets, which are also potentially useful in determining which compounds are likely to have the fewest side effects.
